QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

-- Special Meeting to be held on September 26, 2025 --SAN DIEGO, Sept. 9, 2025 /PRNewswire/ -- In an update to stockholders tod...

 aditxt-plans-fda-submission-for-first-in-human-trials-in-type-1-diabetes-and-stiff-person-syndrome-in-early-2026

Plans to seek FDA submission and approval for first-in-human trials in type 1 diabetes and stiff person syndrome targeted for e...

 aditxt-unveils-bitxbio-its-bitcoin-backed-treasury-strategy

Plan Combines Bitcoin Treasury Strategy and Equity Line to Support 2026 Potential Monetization Events, Starting with Pearsanta&...

 aditxt-files-prospectus-related-to-resale-of-up-to-50m-shares-co-may-issue-and-sell-to-seven-knots-from-time-to-time

https://www.sec.gov/Archives/edgar/data/1726711/000121390025056288/ea0246242-s1_aditxt.htm

 aditxts-pearsanta-receives-irb-approval-from-wcg-clinical-to-initiate-prospective-clinical-study-evaluating-mitomic-endometriosis-test-plans-to-begin-patient-enrollment-in-may-2025

Prospective study to evaluate diagnostic performance and generate real-world data for the Mitomic® Endometriosis Test, a potent...

 aditxt-says-mayo-clinic-pre-clinical-studies-further-validates-findings-of-adi-100-adimunes-lead-therapeutic-candidate-for-autoimmune-diseases

Findings Further Support the Safety Profile and Immunomodulatory Effects of ADI-100, Adimune's Lead Therapeutic Candidate f...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION